Today's Research: Avanir Pharmaceuticals Inc., Warner Chilcott plc, Actavis Inc., and Dynavax Technologies Corp.

LONDON, August 28, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Tuesday, August 27, 2013, the US benchmark indexes fell sharply. The NASDAQ Composite Index fell 2.16%, the Dow Jones Industrial Average fell 1.14%, while the S&P 500 was down 1.59%. Shares in the generic drug manufactures ended on a lower note, tracking losses in the broader market. The major movers included AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Warner Chilcott PLC (NASDAQ: WCRX), Actavis Inc. (NYSE: ACT), and Dynavax Technologies Corporation (NASDAQ: DVAX). AAAResearchReports.com has completed their technical analysis on AVNR, WCRX, ACT, and DVAX and these free reports are accessible by registering at:

http://www.aaaresearchreports.com/register/  

Shares in AVANIR Pharmaceuticals Inc. plummeted on Tuesday, after rising sharply in the previous trading session. The company's shares traded between $4.89 and $5.13 before closing the day at $4.92, down 5.20%. A total of 5.64 million shares were traded, which is above the daily average volume 2.42 million. Despite Tuesday's pullback, the company's shares have gained 4.68% in the last one month and 44.28% in the last three months, outperforming the S&P 500 during the same periods. Furthermore, the company's stock is currently trading above the 50-day and 200-day moving averages. Sign up for free technical research on AVNR at:

http://www.AAAResearchReports.com/AVNR082813.pdf

On Tuesday, Warner Chilcott PLC's shares fell sharply, finishing at $20.87, down 2.66% from the previous closing price of $21.44. The company's shares fluctuated between $20.82 and $21.42. A total of 2.33 million shares were traded, which is below the daily average volume of 3.74 million. The company's stock has gained 4.56% in the last three months, compared to a loss of 1.16% in the S&P 500 during the same period. Additionally, Warner Chilcott PLC's's shares are trading above their 50-day and 200-day moving averages. Be sure to read our latest technical research on WCRX by registering at:

http://www.AAAResearchReports.com/WCRX082813.pdf

Actavis Inc.'s shares also fell sharply on Tuesday as the broader market ended on a declining note. The company's shares hit an intra-day low of $131.03 before ending the day at $131.43, 2.75% down from the previous trading session. A total of 0.95 million shares were traded, which is below the daily average volume of 1.21 million. Despite the recent losses, Actavis Inc.'s shares are trading above their 50-day and 200-day moving averages. Further, the company's shares have gained 3.30% in the last three months, outperforming the S&P 500 which has fallen by 1.16% during the same period. Sign up and read the complimentary report on ACT at:

http://www.AAAResearchReports.com/ACT082813.pdf

Dynavax Technologies Corporation's stock vacillated between $1.28 and $1.31 on Tuesday, before ending the day 1.54% lower at $1.28. A total of 0.83 million shares were traded which is significantly below the daily average volume of 3.09 million. The company's shares have fallen by 3.03% in the last three trading sessions. However, Dynavax Technologies Corporation's shares have gained 2.40% in the last one month, outperforming the S&P 500 which has declined by 3.62% during the same period. The free report on DVAX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/DVAX082813.pdf

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AAAresearchreports.com

SOURCE AAA Research Reports